Paradigm shift in local consolidative therapy for oligometastatic non-small cell lung cancer: a meta-analysis

Christopher Cao\textsuperscript{1,2,3,4}, Adam Chakos\textsuperscript{3}, Allen Guo\textsuperscript{3}, John J. Park\textsuperscript{5}, Tajalli Saghaie\textsuperscript{6}, Prunella Blinman\textsuperscript{7}

\textsuperscript{1}Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney University, Sydney, Australia; \textsuperscript{2}Department of Cardiothoracic Surgery, Concord Repatriation Hospital, Sydney, Australia; \textsuperscript{3}Department of Cardiothoracic Surgery, Collaborative Research Group, Sydney, Australia; \textsuperscript{4}Department of Cardiothoracic Surgery, Lifehouse Cancer Hospital, Sydney, Australia; \textsuperscript{5}Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia; \textsuperscript{6}Department of Respiratory Medicine, \textsuperscript{7}Department of Medical Oncology, Concord Repatriation Hospital, Sydney, Australia

Correspondence to: Christopher Cao. Professor, Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney University, 50 Missenden Road, Camperdown, Sydney, NSW 2050, Australia. Email: drchriscao@gmail.com.

Provenance: This is an invited article commissioned by the Section Editor Dr. Song Xu (Department of lung cancer surgery, Tianjin Medical University General Hospital; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin, China).


Should patients with oligometastatic non-small cell lung cancer (NSCLC) undergo local consolidative therapy (LCT)? That was the question posed by Gomez and colleagues, who should be congratulated on their randomized controlled trial originally published in 2016 in \textit{Lancet Oncology} (1). The trial selected patients with histologically-proven stage IV NSCLC with \(\leq 3\) sites of disease after first-line systemic therapy, prior to randomization to either LCT and maintenance therapy (MT) or maintenance therapy/observation (MTO) alone. Randomization was balanced dynamically according to the number of metastases, response to initial therapy, central nervous system metastases, nodal status, and EGFR/ALK status. The primary endpoint of the trial was progression-free survival (PFS). Although the initial aim was to randomize 94 patients, the study was terminated prematurely after treatment of 49 patients due to detection of a significant superiority in PFS for the LCT group (11.9 vs. 3.9 months; \(P=0.005\)). Local consolidative treatment regimens to the primary and metastatic lesions included hypofractionated radiotherapy, surgery/radiation, chemoradiation, or surgery alone, to treat all sites of disease. MT provided in both arms included pemetrexed, targeted therapy agents, and bevacizumab. The authors concluded in the 2016 publication that aggressive local therapy should be considered in selected patients with oligometastatic stage IV NSCLC, particularly as the benefit of increased PFS was achieved without increasing the incidence of grade \(\geq 3\) adverse events (1). However, it should be noted that the median follow-up at the time was only 12.4 months from the time of randomization due to premature termination by the Data Safety Monitoring Committee.

With prolonged follow-up beyond 38 months, Gomez and colleagues recently presented their updated data in the \textit{Journal of Clinical Oncology} (2). The previously identified key finding persisted, with a significantly longer median PFS in the LCT group compared to the MTO group (14.2 vs. 4.4 months, \(P=0.022\)). Furthermore, median overall survival was also significantly longer in the LCT group (41.2 vs. 17.0 months, \(P=0.017\)). Of additional interest, 15 out of 39 patients who experienced disease progression and then underwent LCT achieved a longer overall survival compared to patients who had disease progression and did not have further LCT. In other words, early LCT was better than no LCT, but late or ‘salvage’ LCT after disease progression was still better than no LCT at all. These findings were supported by another recent trial by Iyengar and colleagues, who randomized patients to stereotactic body radiation therapy (SBRT) and MT versus MT alone (3). In contrast to the Gomez study, oligometastatic disease was...
defined as ≤5 lesions, and patients with targetable mutations were excluded from enrolment. Once again, the trial was terminated early after interim analysis demonstrated significant benefit in PFS in the LCT treatment arm (9.7 vs. 3.5 months, P=0.01), without any increase in toxicities. Although this prospective randomized trial was limited by its sample size to analyze overall survival, larger retrospective series have reported improved median overall survival in patients who underwent LCT, particularly those with limited intrathoracic burden, lack of bony disease, and non-squamous histopathology (4).

In order to summarize the current Level 1 evidence, we performed a meta-analysis using all the identified randomized data in the existing literature. Kaplan-Meier curves from two randomized controlled trials were aggregated using techniques developed by Guyot and colleagues for conducting secondary analysis of survival data (2,3,5). This method involves individual patient data being back-calculated from digitized survival curves while considering time-matched numbers-at-risk. Individual patient data was then combined in a Kaplan-Meier model to generate combined overall survival curves. Hazard ratios (HR) between survival curves were calculated using a Cox proportional hazard model. The threshold for significance was taken as P<0.05. These calculations were performed using R (R foundation for statistical computing, Vienna, Austria), and Matlab R2017b (The MathWorks, Natick, Massachusetts, USA), and are presented in Figure 1. This demonstrated a significantly increased PFS curve for LCT and MT versus MT alone [HR, 0.42; 95% confidence interval (CI), 0.24–0.69; P=0.001]. A summary of study characteristics is presented in Table 1, and it should be noted that a third randomized trial was excluded from analysis due to a lack of individualized data for patients with primary

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Institution</th>
<th>Enrolment period</th>
<th>Follow-up period</th>
<th>LCT (n)</th>
<th>MT (n)</th>
<th>LCT regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gomez, 2019</td>
<td>MD Anderson Cancer Center, USA; London Health Sciences Center, Canada; Colorado School of Medicine, USA</td>
<td>2012–2016</td>
<td>38.8 months</td>
<td>25</td>
<td>24</td>
<td>Surgery or radiation</td>
</tr>
<tr>
<td>Iyengar, 2017</td>
<td>University of Texas Southwestern Medical Center, USA</td>
<td>2014–2016</td>
<td>9.6 months</td>
<td>14</td>
<td>15</td>
<td>SBRT followed by maintenance chemotherapy</td>
</tr>
</tbody>
</table>

LCT, local consolidative therapy; MT, maintenance therapy; NSCLC, non-small cell lung cancer; SBRT, stereotactic body radiation therapy.

Figure 1 PFS for LCT and MT versus MT alone for patients with oligometastatic NSCLC. Curves generated by aggregation of published data from randomized controlled trials. PFS, progression-free survival; LCT, local consolidative therapy; MT, maintenance therapy; NSCLC, non-small cell lung cancer.

Table 1 Summary of study characteristics for randomized controlled trials comparing LCT and MT versus MT alone in patients with oligometastatic stage IV NSCLC
lung cancer (6).

How will these findings affect clinical practice in the contemporary era? Since the closure of enrolment in the Gomez trial in January 2016, the introduction of immunotherapy has led to a paradigm shift in the treatment of advanced stage NSCLC (7,8). With prolonged PFS and lower toxicity profile, it is foreseeable that a higher proportion of patients with oligometastatic NSCLC treated by immunotherapeutic agents will achieve stable disease and become eligible candidates for LCT. Similarly, targeted therapy has continued to evolve with maturing data and emergence of new drugs. Gomez and colleagues have commenced enrolment in a phase II randomized trial comparing osimertinib with or without LCT (ClinicalTrials.gov identifier: NCT03410043).

Regarding local consolidative treatment modalities, the popularization of SBRT and minimally invasive thoracic surgery have improved the tolerability and efficacy of LCT in the contemporary era (9,10). Compared to traditional radiotherapy, SBRT delivers fewer fractions of high-dose radiation with increased precision and higher biologically effective dose, resulting in reduced toxicity and improved local control (11). Conventional and robotic video-assisted thoracoscopic surgery have both been associated with reduced perioperative morbidity whilst maintaining long-term oncological efficacy when compared to the traditional thoracotomy approach in the treatment of NSCLC (10,12,13). With these advancements in systemic therapy and LCT, it is hoped that a greater proportion of patients diagnosed with stage IV NSCLC will be eligible for lower risk and more effective local therapies to improve their PFS and overall survival. Future studies should be consistent in the definition of oligometastatic disease, aim to identify important prognostic factors that could help to refine patient selection, and further assess quality of life and cost effectiveness outcomes. Discussion and consideration of LCT for this growing cohort of patients in a multidisciplinary team setting will be critical to ensure the optimal treatment for individual patients.

Acknowledgments
None.

Footnote
Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References


